Genomics

1/10 We’re excited to announce the publication of our work with @StanfordMed, examining the premature deaths that would be saved if PRS-guided screening was introduced across seven common disease screening programs nature.com/articles/s4146…

2 days to go! Join us for a live discussion on how AI is being applied to #humangeneticdata for #drugdiscovery & development. Hear from: • Alex Eavis, Genomics • Mike Tarselli, @AWScloud • Vincent Plagnol, Genomics 21st May 2-3pm BST | 9-10AM EDT eu1.hubs.ly/H0vkkF60

⏳ One week to go! Join our upcoming webinar, AI in Human Genetics: Where it Helps, Where It Doesn’t, and What Really Matters, with experts from Genomics and @awscloud. 21st May 2-3pm BST | 9-10AM EDT 🎫eu1.hubs.ly/H0vkgB80

We hit 20,000 followers on @LinkedIn this week! 🎉 To everyone who’s followed, liked, commented, shared, or simply taken a moment to read our content: thank you. Here’s to the next chapter - and the next milestone! 🥳 #20K #LinkedIn #socialmedia #growth

📢[FOR MEDIA] Genomics and Greywolf Therapeutics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases. 📰Press release: eu1.hubs.ly/H0tX19r0 #Genomics #CompanyNews #IndustryNews #Innovation

For our upcoming webinar, we’re bringing together experts to explore "#AI in #HumanGenetics: Where It Helps, Where It Doesn’t, & What Really Matters" 🎤 Alex Eavis, Chief Product & Tech Officer 🎤 Vincent Plagnol, CSO 🎤 More speakers coming soon 👀 eu1.hubs.ly/H0tVzHR0

We're excited to share that our webinar series #TheGenomicsRevolution is returning on 21st May, starting with: #AI in #HumanGenetics: Where it Helps, Where it Doesn't, and What Really Matters 📅 21st May 🕰️ 2:00 PM - 3:00 PM BST 👉 Register here: eu1.hubs.ly/H0tLjZz0

We were honoured to attend @thetimes 100 Tech awards, where we celebrated being named one of Britain’s fastest growing private tech companies for the second year in a row. 🏆 #100Tech @genemodeller

🧬 We recently celebrated a huge milestone with the opening our flagship London office. Now, we’re turning to #TheNextSequence’ - the next stage in our growth journey. We’re excited to share this new chapter with you. Stay tuned! #Genomics #UKInnovation

It also highlights the NHS-backed @ukfuturehealth and insights from our CEO & Co-Founder Peter Donnelly on how genetic sequencing could inform earlier treatment decisions, including statins for people in their 20s & 30s.

The piece explores how polygenic risk scores (PRS) could help identify heart attack risk earlier in life, enabling preventative care and earlier interventions for those most at risk.

We’re delighted Genomics was featured in The i Paper, discussing how advances in genetic risk prediction could reshape how we prevent heart disease — even in younger adults. 📖eu1.hubs.ly/H0sGJXK0 #Genomics #PrecisionMedicine #PRS #Cardiology

@zubirahmed We were thrilled to welcome 50+ senior leaders from pharma, healthcare, private healthcare & government to celebrate our new London office! Hearing Dr Zubir Ahmed MP call Genomics “the jewels in our crown” was a truly exciting moment. Thank you to everyone who joined us!

On Feb 25th, we officially opened our flagship London office in the Knowledge Quarter! 🎉Inaugurated by Dr @ZubirAhmed MP and Steve Bates OBE 📖 Read more: eu1.hubs.ly/H0sJh290

📢[FOR MEDIA] Minister for Health Innovation Dr Zubir Ahmed MP and Executive Chair for the Office of Life Sciences Steve Bates OBE open Genomics’ flagship office, as it unveils Agentic AI capabilities within Mystra drug discovery Platform 📰Press release: bit.ly/3ZRGLgy

On #InternationalDayofWomenandGirlsinScience, we're celebrating the incredible contributions of the women in science-related roles at Genomics. We are proud that women constitute 50% of our colleagues in these critical positions, powering the work we do. Thank you! 💙

10/10 Our thanks as ever to participants and investigators providing source data. Co-authors include @DrJackOSullivan @melisa_chuong @Deborah_J_T @mikeweale @fa7gen Nilesh Samani @DanielJohnWells @VincentPlagnol @gil_mcvean @euanashley @seamusharrison @genemodeller @Genomicsltd.

9/10 We therefore conclude that knowledge of genetic risk, measured using PRS, has the potential to deliver substantial public health benefits when aggregated across conditions, and could reduce premature mortality by tailoring existing screening programs.

1/10 We’re excited to announce the publication of our work with @StanfordMed, examining the premature deaths that would be saved if PRS-guided screening was introduced across seven common disease screening programs nature.com/articles/s4146…